147 related articles for article (PubMed ID: 37478120)
1. TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma.
Shi K; Liu XL; Guo Q; Zhang YQ; Fan ST; Dai L; Jiang N; Li D
PLoS One; 2023; 18(7):e0285817. PubMed ID: 37478120
[TBL] [Abstract][Full Text] [Related]
2. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
[TBL] [Abstract][Full Text] [Related]
3. The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma.
Tong S; Jiang N; Wan JH; Chen CR; Wang SH; Wu CY; Guo Q; Xiao XY; Huang H; Zhou T
BMC Cancer; 2023 Mar; 23(1):275. PubMed ID: 36973678
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.
Cheng P; Ma J; Zheng X; Zhou C; Chen X
Sci Rep; 2021 Jun; 11(1):12608. PubMed ID: 34131259
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Ma H; Feng PH; Yu SN; Lu ZH; Yu Q; Chen J
BMC Cancer; 2022 May; 22(1):543. PubMed ID: 35562682
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer.
Chen P; Yang Y; Zhang Y; Jiang S; Li X; Wan J
Aging (Albany NY); 2020 Feb; 12(4):3371-3387. PubMed ID: 32074080
[TBL] [Abstract][Full Text] [Related]
7. High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma.
Lu X; Ying Y; Zhang W; Li R; Zhang J
Cell Biol Int; 2023 Jan; 47(1):201-215. PubMed ID: 36208091
[TBL] [Abstract][Full Text] [Related]
8. Expression of transmembrane protein 41A is associated with metastasis via the modulation of E‑cadherin in radically resected gastric cancer.
Lin B; Xue Y; Qi C; Chen X; Mao W
Mol Med Rep; 2018 Sep; 18(3):2963-2972. PubMed ID: 30015937
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value and Immune-Infiltration Pattern of
Yang Z; Shen X; Luo S; Li Y
Dis Markers; 2022; 2022():9621701. PubMed ID: 35126794
[TBL] [Abstract][Full Text] [Related]
10. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
11. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma.
Tao Y; Liang B
Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917
[TBL] [Abstract][Full Text] [Related]
12. SUMF1 overexpression promotes tumorous cell growth and migration and is correlated with the immune status of patients with glioma.
Zhang P; Liu Z; Wang YY; Luo HJ; Yang CZ; Shen H; Wu HT; Li JH; Zhao HX; Ran QS
Aging (Albany NY); 2024 Mar; 16(5):4699-4722. PubMed ID: 38460946
[TBL] [Abstract][Full Text] [Related]
13. Mining of clinical and prognosis related genes in the tumor microenvironment of endometrial cancer: A field synopsis of observational study.
Li W; Qin Y; Chen X; Wang X
Medicine (Baltimore); 2023 Jun; 102(25):e34047. PubMed ID: 37352078
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating immune cell score as an independent prognostic predictor for endometrial carcinoma: Insights from a comprehensive analysis of the immune landscape.
Zhang L; Zhu Q; Zhao Q; Lin X; Song H; Liu H; Zhu G; Lu S; Cao B
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1939. PubMed ID: 38017652
[TBL] [Abstract][Full Text] [Related]
15. Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.
Wu Y; Wang J; Ge L; Hu Q
Oxid Med Cell Longev; 2022; 2022():5130648. PubMed ID: 35251475
[TBL] [Abstract][Full Text] [Related]
16. The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling.
Xu L; Fang Q; Miao Y; Xu M; Wang Y; Sun L; Jia X
Bioengineered; 2021 Dec; 12(1):3467-3484. PubMed ID: 34251980
[TBL] [Abstract][Full Text] [Related]
17. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
18. A seven-m6A regulator-related CpG site-based prognostic signature for endometrial carcinoma.
Zhang X; Pang X; Huang Y; Qian S
Medicine (Baltimore); 2021 Jul; 100(29):e26648. PubMed ID: 34398021
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
Luo L; Zhou H; Su H
BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
Li BL; Wan XP
J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
